(PPH) VanEck Pharmaceutical - Ratings and Ratios
Pharmaceuticals, Biotechnology, Large-Cap, US-Listed
Dividends
| Dividend Yield | 1.91% |
| Yield on Cost 5y | 3.24% |
| Yield CAGR 5y | 11.54% |
| Payout Consistency | 90.8% |
| Payout Ratio | - |
| Risk via 10d forecast | |
|---|---|
| Volatility | 16.9% |
| Value at Risk 5%th | 27.5% |
| Relative Tail Risk | -0.83% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.60 |
| Alpha | 7.19 |
| CAGR/Max DD | 0.64 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.486 |
| Beta | 0.401 |
| Beta Downside | 0.431 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.06% |
| Mean DD | 4.84% |
| Median DD | 3.79% |
Description: PPH VanEck Pharmaceutical October 23, 2025
The VanEck Pharmaceutical ETF (NASDAQ: PPH) is a non-diversified fund that must allocate at least 80 % of its assets to securities that track its benchmark index, which consists of U.S. exchange-listed pharmaceutical companies-including common stocks and depositary receipts from both domestic medium-cap firms and foreign issuers listed in the U.S.
Key sector drivers that can affect PPH’s performance include the U.S. FDA’s drug-approval pipeline (which averaged 45 approvals per year in 2023, a 12 % increase YoY) and the industry-wide rise in R&D spending, now exceeding $200 billion annually-a metric that often correlates with future earnings growth for pharma firms. As of the latest filing, PPH’s expense ratio stands at 0.45 % and its assets under management are roughly $300 million, giving investors a relatively low-cost, concentrated exposure to the pharma space.
If you want to see how ValueRay’s proprietary scoring system evaluates ETFs like PPH, a quick look at its platform can provide a data-driven perspective that may help refine your investment thesis.
What is the price of PPH shares?
Over the past week, the price has changed by +0.73%, over one month by +8.90%, over three months by +13.89% and over the past year by +14.56%.
Is PPH a buy, sell or hold?
What are the forecasts/targets for the PPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 113.2 | 11.9% |
PPH Fundamental Data Overview December 02, 2025
Beta = 0.59
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.18b USD (1.18b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.18b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.18b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.49% (E(1.18b)/V(1.18b) * Re(7.49%) + (debt-free company))
Discount Rate = 7.49% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for PPH ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle